The pharmaceutical company Celltrion claims to have announced that it has developed a substance that has been shown to be effective in treating COVID-19 patients. Researchers in South Korea are conducting clinical trials with the substance they have developed that has been shown to be effective in treating COVID-19, according to Yonhap. The substance developed by Celltrion is called CT-P59 and will be administered to about 1,000 people who have contracted the new coronavirus.

These include both asymptomatic patients and those who have been in contact with COVID-19 patients.

The South Korean pharmaceutical company has announced that it will develop new clinical trials after its researchers successfully completed the first phase of clinical trials in a number of 32 healthy volunteers who did not contract the new coronavirus. It should be noted that separately, CT-P59 is currently in the second and third phase of clinical trials not only in South Korea, but also in other countries around the world, including Romania.

Celltrion is currently conducting the second phase of clinical trials in approximately 300 people with mild and severe symptoms of the virus. This research will allow the specialists involved in the project to better verify the effectiveness of CT-P59 against COVID-19 but also the safety it offers to those who are being treated.

The third phase of clinical trials will be carried out in a number of approximately 720 people, and the goal is to determine how effective the new substance is against viral infections, as reported by the pharmaceutical giant.

Representatives of the medical company Celltrion said that, in addition to South Korea, clinical trials for the new substance, CT-P59, were requested in the United States, Romania and three other countries. This is part of their ongoing efforts to find a viable treatment to combat the COVID-19 pandemic.